CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
High-dose endorectal brachytherapy (HDRBT)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01226979
NCT01226979N/ACompleted
CompareCT.gov

Phase II Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 22, 2010·Updated Feb 28, 2025

In Brief

A clinical study evaluating High-dose endorectal brachytherapy (HDRBT) for Rectal Cancer. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum). In this study we want to try to decrease side effects and shorten the course of radiation treatment for patients with cancer of their rectum by using a high-dose rate endorectal brachytherapy (HDRBT). This is a different form of radiation than what is normally given (CRT). With HDRBT, the radiation is given through an applicator placed into the bowel next to the tumor. The radiation is directed at the tumor and a small area around it.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2010
Enrollment StartOct 26, 2010
Primary CompletionSep 23, 2016
Study CompletionJul 31, 2018
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 15.7 years ago

Interventions

High-dose endorectal brachytherapy (HDRBT)radiation

The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.